Bibr 796 bs (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02209779 (ClinicalTrials.gov) | May 2001 | 5/8/2014 | Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis | A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD | Arthritis, Rheumatoid | Drug: BIBR 796 BS;Drug: Placebo | Boehringer Ingelheim | NULL | Completed | 18 Years | 75 Years | Both | 167 | Phase 2 | NULL |